Figure 1.
The effects of Pd(II) complexes (C1-C5) and ligands (L1-L5) on the viability of human prostate cancer cells DU-145.
Table 1.
IC50 values for ligands L1-L5, Pd(II) complexes C1-C5 and cisplatin after 24, 48, and 72h drug exposure.
| 24h | 48h | 72h | |
|---|---|---|---|
| L1 | >200 | >200 | >200 |
| L2 | >200 | >200 | >200 |
| L3 | >200 | >200 | >200 |
| L4 | >200 | >200 | >200 |
| L5 | >200 | >200 | >200 |
| C1 | 82,9 | 50,3 | 41,7 |
| C2 | 98,7 | 47,8 | 26,21 |
| C3 | 60,8 | 44,7 | 36,5 |
| C4 | 134,9 | 59,1 | 47,6 |
| C5 | 111,8 | 55,1 | 38,9 |
| cisplatin | 134,5 | 57,2 | 49,2 |
Figure 2.
Pd(II) complexes (C1-C5) reduce the viability of treated DU-145 cells predominantly by induction of apoptosis
Figure 3.
Pd(II) complexes (C2-C5) induce cell cycle arrest of treated DU-145 cells.
Figure 4.
Pd(II) complexes C1-C5 induce apoptosis of human prostate cancer cells DU-145 via the mitochondrial pathway.